Research blog
May 11, 2026 Research use only

CJC-1295 + Ipamorelin Research Notes

Selected PubMed sources, evidence limits, and current BioPep USA catalog and documentation status for CJC-1295 + Ipamorelin. Research use only.

CJC-1295 2D compound structure
Research-use-only scope: This article organizes published sources and BioPep USA records. It does not provide preparation, dosing, injection, human-use, animal-use, therapeutic, diagnostic, cosmetic, or clinical guidance.

CJC-1295 and Ipamorelin are distinct compounds. The selected sources describe each component separately rather than the exact 5/5mg blend.

Questions covered by the selected literature

  • How CJC-1295 has been studied as a long-acting GHRH analogue
  • How Ipamorelin was characterized as a selective secretagogue
  • Why separate component studies cannot be treated as a blend study

Evidence limits

One cited record reports a controlled CJC-1295 study, one characterizes Ipamorelin, and one addresses synthetic GHRH-analogue detection. None tests the BioPep USA blend.

A paper should be read according to its own model, methods, controls, and endpoints. Cell, animal, analytical, review, and human records are not interchangeable.

Selected PubMed sources

  1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. J Clin Endocrinol Metab. 2006 Mar. PMID: 16352683.
  2. Ipamorelin, the first selective growth hormone secretagogue.. Eur J Endocrinol. 1998 Nov. PMID: 9849822.
  3. Advances in the detection of growth hormone releasing hormone synthetic analogs.. Drug Test Anal. 2021 Nov. PMID: 34665524.

BioPep USA record

BioPep USA currently lists CJC-1295 + Ipamorelin. Use the product page for current options and the documentation page for lot records.

Last reviewed: July 20, 2026.